Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of “Hold” from Brokerages
Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) have been given a consensus recommendation of “Hold” by the fourteen brokerages that are currently covering the company. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $77.13.
PCRX has been the topic of several recent research reports. Cowen and Company restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 20th. Wedbush restated an “outperform” rating and set a $109.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, September 21st. Zacks Investment Research lowered Pacira Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. Mizuho restated a “buy” rating and set a $64.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, July 20th. Finally, BMO Capital Markets initiated coverage on Pacira Pharmaceuticals in a report on Tuesday, June 28th. They set an “underperform” rating and a $36.00 price target on the stock.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.01% during mid-day trading on Monday, reaching $35.01. 597,469 shares of the company traded hands. The firm’s market capitalization is $1.31 billion. The company’s 50 day moving average price is $38.81 and its 200 day moving average price is $44.13. Pacira Pharmaceuticals has a 12-month low of $31.08 and a 12-month high of $80.25.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.16. Pacira Pharmaceuticals had a positive return on equity of 0.02% and a negative net margin of 4.21%. The company had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. During the same quarter in the prior year, the firm posted $0.20 EPS. Pacira Pharmaceuticals’s quarterly revenue was up 17.8% compared to the same quarter last year. Equities research analysts predict that Pacira Pharmaceuticals will post $0.44 EPS for the current year.
In related news, President James S. Scibetta sold 25,000 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.21, for a total transaction of $1,130,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David M. Stack sold 15,000 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.32, for a total value of $679,800.00. The disclosure for this sale can be found here. Insiders own 6.90% of the company’s stock.
Several large investors have recently modified their holdings of PCRX. FMR LLC boosted its stake in shares of Pacira Pharmaceuticals by 19.1% in the second quarter. FMR LLC now owns 5,567,088 shares of the company’s stock worth $187,778,000 after buying an additional 892,511 shares during the period. Vanguard Group Inc. boosted its stake in shares of Pacira Pharmaceuticals by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,587,221 shares of the company’s stock worth $87,268,000 after buying an additional 64,898 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Pacira Pharmaceuticals by 0.6% in the second quarter. BlackRock Fund Advisors now owns 1,591,688 shares of the company’s stock worth $53,688,000 after buying an additional 9,454 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of Pacira Pharmaceuticals by 92.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,333,868 shares of the company’s stock worth $44,991,000 after buying an additional 640,814 shares during the period. Finally, State Street Corp boosted its stake in shares of Pacira Pharmaceuticals by 8.0% in the second quarter. State Street Corp now owns 1,197,912 shares of the company’s stock worth $40,406,000 after buying an additional 88,301 shares during the period.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.
Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.